All Publications

Journals

• Seckl MJ; Savage PM; Hancock BW; Berkowitz RS; Goldstein DP; Lurain JR; Schink JC; Cagayan FM; et al. (22 Feb 2010). "Hyperglycosylated hCG in the management of quiescent and chemorefractory gestational trophoblastic diseases". Gynecol Oncol. DOI.
• McGrath S; Short D; Harvey R; Schmid P; Savage PM; Seckl MJ. (2 Mar 2010). The management and outcome of women with post-hydatidiform mole 'low-risk' gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1). Br J Cancer. 102:810-814. DOI.
• Dhillon T; Mauri FA; Bellezza G; Cagini L; Barbareschi M; North BV; Seckl MJ. (Mar 2010). Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer. J Thorac Oncol. 5:314-319. DOI.
• Pardo OE; Latigo J; Jeffery RE; Nye E; Poulsom R; Spencer-Dene B; Lemoine NR; Stamp GW; et al. (15 Nov 2009). The Fibroblast Growth Factor Receptor Inhibitor PD173074 Blocks Small Cell Lung Cancer Growth In vitro and In vivo. CANCER RES. 69:8645-8651. DOI.
• Seckl M; Pardo OE; Lara R; Mauri F; Bates P; Zicha D; Downward J. (Sep 2009). RNAi library screen reveals RSK1 as a key regulator of lung cancer metastasis. J THORAC ONCOL. 4:S559-S560.
• Seckl MJ; Pardo OE; Aboagye EO; Latigo J; Stamp G; Lemoine N; Spencer-Dean B. (Sep 2009). The FGF receptor (FGFR) inhibitor PD0173074 blocks SCLC growth in vitro and in vivo. J THORAC ONCOL. 4:S385-S385.
• Newsom-Davis T; Poulter D; Gray R; Ameen M; Lindsay I; Papanikolaou K; Butler-Manuel S; Christmas T; et al. (18 Jun 2009). Case report: Malignant teratoma of the uterine corpus. BMC CANCER. 9. DOI.
• Wang CM; Dixon PH; Decordova S; Hodges MD; Sebire NJ; Ozalp S; Fallahian M; Sensi A; et al. (Aug 2009). Identification of 13 novel NLRP7 mutations in 20 families with recurrent hydatidiform mole; missense mutations cluster in the leucine-rich region. J MED GENET. 46:569-575. DOI.
• Schmid P; Nagai Y; Agarwal R; Hancock B; Savage PM; Sebire NJ; Lindsay I; Wells M; et al. (4 Jul 2009). Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. LANCET. 374:48-55. DOI.
• Kerkmeijer LG; Thomas CM; Harvey R; Sweep FC; Mitchell H; Massuger LF; Seckl MJ. (17 Mar 2009). External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease. BRIT J CANCER. 100:979-984. DOI.
• Marinov M; Ziogas A; Pardo OE; Tan LT; Dhillon T; Mauri FA; Lane HA; Lemoine NR; et al. (15 Feb 2009). AKT/mTOR Pathway Activation and BCL-2 Family Proteins Modulate the Sensitivity of Human Small Cell Lung Cancer Cells to RAD001. CLIN CANCER RES. 15:1277-1287. DOI.
• MacKinnon AC; Tufail-Hanif U; Wheatley M; Rossi AG; Haslett C; Seckl M; Sethi T. (Jan 2009). Targeting V-1A-vasopressin receptors with [Arg(6), D-Trp(7,9), N(me)Phe(8)]-substance P (6-11) identifies a strategy to develop novel anti-cancer therapies. BRIT J PHARMACOL. 156:36-47. DOI.
• Kemp SJ; Thorley AJ; Gorelik J; Seckl MJ; O'Hare MJ; Arcaro A; Korchev Y; Goldstraw P; et al. (Nov 2008). Immortalization of Human Alveolar Epithelial Cells to Investigate Nanoparticle Uptake. AM J RESP CELL MOL. 39:591-597. DOI.
• Sebire NJ; Fisher RA; Williams S; Prendergast G; Savage P; Seckl M. (Oct 2008). Indoleamine 2,3-Dioxygenase Expression in Gestational Trophoblastic Disease Implications for Development of Immunotherapeutic Approaches. J REPROD MED. 53:789-792.
• Savage P; Seckl M; Short D. (Oct 2008). Practical issues in the management of low-risk gestational trophoblast tumors. J Reprod Med. 53:774-780.
• Patten DK; Lindsay I; Fisher R; Sebire N; Savage PM; Seckl MJ. (1 Nov 2008). Gestational choriocarcinoma mimicking a uterine adenocarcinoma. J Clin Oncol. 26:5126-5127. DOI.
• Sebire NJ; Seckl MJ. (23 Aug 2008). Gestational trophoblastic disease: current management of hydatidiform mole. BRIT MED J. 337. DOI.
• Lim AK; Patel D; Patel N; Hawtin K; Dayal L; Schmid P; Savage P; Seckl MJ. (Aug 2008). Pelvic imaging in gestational trophoblastic neoplasia. J Reprod Med. 53:575-578.
• Harvey RA; Pursglove HD; Schmid P; Savage PM; Mitchell HD; Seckl MJ. (Aug 2008). Human chorionic gonadotropin free beta-subunit measurement as a marker of placental site trophoblastic tumors. J Reprod Med. 53:643-648.
• Hackshaw A; Farrant H; Bulley S; Seckl MJ; Ledermann JA. (Jun 2008). Setting up non-commercial clinical trials takes too long in the UK: findings from a prospective study. J ROY SOC MED. 101:299-304. DOI.
• Wang J; Short D; Sebire NJ; Lindsay I; Newlands ES; Schmid P; Savage PM; Seckl MJ. (Sep 2008). Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). Ann Oncol. 19:1578-1583. DOI.
• Collier K; Schink C; Young AM; How K; Seckl M; Savage P. (Mar 2008). Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity. J Oncol Pharm Pract. 14:51-55. DOI.
• Ong TA; Winkler MH; Savage PM; Seckl MJ; Christmas TJ. (Jul 2008). Retroperitoneal lymph node dissection after chemotherapy in patients with elevated tumour markers: indications, histopathology and outcome. BJU Int. 102:198-202. DOI.
• Marinov M; Ziogas A; Pardo OE; Tan LT; Lane HA; Lemoine NR; Zangemeister-Wittke U; Seckl MJ; et al. (Dec 2007). Akt/mTOR pathway activation and Bcl-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001 (Everolimus). MOL CANCER THER. 6:3409S-3409S.
• Patterson DM; Murugaesu N; Holden L; Seckl MJ; Rustin GJS. (Jan 2008). A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites. INT J GYNECOL CANCER. 18:43-50. DOI.
• Oladipo A; Mathew J; Oriolowo A; Lindsay I; Fisher R; Seckl M; Yiannakis D. (Oct 2007). Nongestational choriocarcinoma arising from a primary ovarian tumour. BJOG-INT J OBSTET GY. 114:1298-1300. DOI.
• Fisher RA; Savage PM; MacDermott C; Hook J; Sebire NJ; Lindsay I; Seckl MJ. (Dec 2007). The impact of molecular genetic diagnosis on the management of women with hCG-producing malignancies. Gynecol Oncol. 107:413-419. DOI.
• Willis SF; Winkler M; Savage P; Seckl MJ; Christmas TJ. (Oct 2007). Repeat retroperitoneal lymph-node dissection after chemotherapy for metastatic testicular germ cell tumour. BJU INT. 100:809-812.
• Ngan S; Seckl MJ. (Sep 2007). Gestational trophoblastic neoplasia management: an update. CURR OPIN ONCOL. 19:486-491.
• Pfeffer PE; Sebire N; Lindsay L; McIndoe A; Lim A; Seckl MJ. (Aug 2007). Fertility-sparing partial hysterectomy for placental-site trophoblastic tumour. LANCET ONCOL. 8:744-746.
• Palmieri C; Dhillon T; Fisher RA; Young AM; Short D; Mitchell H; Aghajanian C; Savage PM; et al. (Jul 2007). Management and outcome of healthy women with a persistently elevated beta-hCG. GYNECOL ONCOL. 106:35-43. DOI.
• Wang J; Cook G; Frank J; Dina R; Livni N; Lynn J; Fleming W; Seckl MJ. (2007). Case report: PET/CT, a cautionary tale. BMC Cancer. 7:147. DOI.
• Doumplis D; Al-Khatib K; Sieunarine K; Lindsay I; Seckl M; Bridges J; Smith JR. (Sep 2007). A review of the management by hysterectomy of 25 cases of gestational trophoblastic tumours from March 1993 to January 2006. BJOG. 114:1168-1171. DOI.
• Sebire NJ; Foskett M; Short D; Savage P; Stewart W; Thomson M; Seckl MJ. (Jun 2007). Shortened duration of human chorionic gonadotrophin surveillance following complete or partial hydatidiform mole: evidence for revised protocol of a UK regional trophoblastic disease unit. BJOG. 114:760-762. DOI.
• Milingos D; Doumplis D; Savage P; Seckl M; Lindsay I; Smith JR. (Jul 2007). Placental site trophoblastic tumor with an ovarian metastasis. Int J Gynecol Cancer. 17:925-927. DOI.
• Powles T; Savage PM; Stebbing J; Short D; Young A; Bower M; Pappin C; Schmid P; et al. (12 Mar 2007). A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. Br J Cancer. 96:732-737. DOI.
• Arcaro A; Aubert M; Espinosa del Hierro ME; Khanzada UK; Angelidou S; Tetley TD; Bittermann AG; Frame MC; et al. (May 2007). Critical role for lipid raft-associated Src kinases in activation of PI3K-Akt signalling. Cell Signal. 19:1081-1092. DOI.
• Mitchell H; Seckl MJ. (2 Jan 2007). Discrepancies between commercially available immunoassays in the detection of tumour-derived hCG. MOL CELL ENDOCRINOL. 260:310-313. DOI.
• Fowler DJ; Lindsay I; Seckl MJ; Sebire NJ. (Jan 2007). Histomorphometric features of hydatidiform moles in early pregnancy: relationship to detectability by ultrasound examination. Ultrasound Obstet Gynecol. 29:76-80. DOI.
• Dhillon T; Palmieri C; Sebire NJ; Lindsay I; Newlands ES; Schmid P; Savage PM; Frank J; et al. (Nov 2006). Value of whole body (18)FDG-PET to identify the active site of gestational trophoblastic neoplasia. JOURNAL OF REPRODUCTIVE MEDICINE. 51:879-887.
• Mitchell H; Bagshawe KD; Newlands ES; Savage P; Seckl MJ. (Nov 2006). Importance of accurate human chorionic gonadotropin measurement in the treatment of gestational trophoblast disease and testicular cancer. JOURNAL OF REPRODUCTIVE MEDICINE. 51:868-870.
• Powles T; Young A; Sammit A; Stebbing J; Short D; Bower M; Savage PM; Seckl MJ; et al. (6 Nov 2006). The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours. BRIT J CANCER. 95:1145-1147. DOI.
• Murugaesu N; Schmid P; Dancey G; Agarwal R; Holden L; McNeish I; Savage PM; Newlands ES; et al. (20 Oct 2006). Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol. 24:4862-4866. DOI.
• Zhao J; Xiang Y; Huang SZ; Wan XR; Cui QC; Seckl MJ; Fisher RA. (Oct 2006). [Genetic heterogeneity for familial recurrent hydatidiform mole]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 23:511-514.
• Willis S; Goldstraw M; Christmas T; Hrouda D; Seckl M. (Sep 2006). Fibroblast growth factor 2 (FGF-2), a growth factor known to cause chemoresistance in prostate cancer, cannot prevent death induced by a novel Src kinase inhibitor in-vltro. EUR UROL SUPPL. 5:796-796.
• Cole LA; Butler SA; Khanlian SA; Giddings A; Muller CY; Seckl MJ; Kohorn EI. (Aug 2006). Gestational trophoblastic diseases: 2. Hyperglycosylated hCG as a reliable marker of active neoplasia. GYNECOL ONCOL. 102:151-159. DOI.
• Pardo OE; Wellbrock C; Khanzada UK; Aubert M; Arozarena I; Davidson S; Bowen F; Parker PJ; et al. (12 Jul 2006). FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. EMBO J. 25:3078-3088. DOI.
• Burke B; Sebire NJ; Moss J; Hodges MD; Seckl MJ; Newlands ES; Fisher RA. (Nov 2006). Evaluation of deletions in 7q11.2 and 8p12-p21 as prognostic indicators of tumour development following molar pregnancy. Gynecol Oncol. 103:642-648. DOI.
• Dhillo WS; Savage P; Murphy KG; Chaudhri OB; Patterson M; Nijher GM; Foggo VM; Dancey GS; et al. (Nov 2006). Plasma kisspeptin is raised in patients with gestational trophoblastic neoplasia and falls during treatment. Am J Physiol Endocrinol Metab. 291:E878-E884. DOI.
• Allen SD; Lim AK; Seckl MJ; Blunt DM; Mitchell AW. (Apr 2006). Radiology of gestational trophoblastic neoplasia. Clin Radiol. 61:301-313. DOI.
• Khan S; Dancey G; Lindsay I; Sebire NJ; Fisher RA; Seckl MJ; Savage P. (Mar 2006). Placental site trophoblastic tumour derived from an oocyte donation pregnancy. BJOG. 113:344-346. DOI.
• Khanzada UK; Pardo OE; Meier C; Downward J; Seckl MJ; Arcaro A. (9 Feb 2006). Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling. Oncogene. 25:877-887. DOI.
• Zhao J; Moss J; Sebire NJ; Cui QC; Seckl MJ; Xiang Y; Fisher RA. (Feb 2006). Analysis of the chromosomal region 19q13.4 in two Chinese families with recurrent hydatidiform mole. Hum Reprod. 21:536-541. DOI.
• Powles T; Savage P; Short D; Young A; Pappin C; Seckl MJ. (16 Jan 2006). Residual lung lesions after completion of chemotherapy for gestational trophoblastic neoplasia: should we operate?. Br J Cancer. 94:51-54. DOI.
• Fowler DJ; Lindsay I; Seckl MJ; Sebire NJ. (Jan 2006). Routine pre-evacuation ultrasound diagnosis of hydatidiform mole: experience of more than 1000 cases from a regional referral center. Ultrasound Obstet Gynecol. 27:56-60. DOI.
• Onganer PU; Seckl MJ; Djamgoz MB. (28 Nov 2005). Neuronal characteristics of small-cell lung cancer. Br J Cancer. 93:1197-1201. DOI.
• Savage P; Seckl MJ. (Oct 2005). The role of repeat uterine evacuation in trophoblast disease. GYNECOL ONCOL. 99:251-252.
• El-Helw LM; Seckl MJ; Haynes R; Evans LS; Lorigan PC; Long J; Kanfer EJ; Newlands ES; et al. (19 Sep 2005). High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia. Br J Cancer. 93:620-621. DOI.
• Palmieri C; Fisher RA; Sebire NJ; Lindsay I; Smith JR; McCluggage WG; Savage P; Seckl MJ. (20 Aug 2005). Placental site trophoblastic tumour arising from a partial hydatidiform mole. Lancet. 366:688. DOI.
• Sebire NJ; Lindsay I; Fisher RA; Savage P; Seckl MJ. (Jul 2005). Overdiagnosis of complete and partial hydatidiform mole in tubal ectopic pregnancies. Int J Gynecol Pathol. 24:260-264.
• Wenzel L; Dogan-Ates A; Habbal R; Berkowitz R; Goldstein DP; Bernstein M; Kluhsman BC; Osann K; et al. (2005). Defining and measuring reproductive concerns of female cancer survivors. J Natl Cancer Inst Monogr. 94-98. DOI.
• Sebire NJ; Lindsay I; Fisher RA; Seckl MJ. (Jan 2005). Intraplacental choriocarcinoma: experience from a tertiary referral center and relationship with infantile choriocarcinoma. Fetal Pediatr Pathol. 24:21-29.
• Sebire NJ; Foskett M; Fisher RA; Lindsay I; Seckl MJ. (2005). Persistent gestational trophoblastic disease is rarely, if ever, derived from non-molar first-trimester miscarriage. Med Hypotheses. 64:689-693. DOI.
• Sarwar N; Newlands ES; Seckl MJ. (Nov 2004). Gestational trophoblastic neoplasia: the management of relapsing patients and other recent advances. Curr Oncol Rep. 6:476-482.
• Seckl MJ; Gillmore R; Foskett M; Sebire NJ; Rees H; Newlands ES. (21 Aug 2004). Routine terminations of pregnancy--should we screen for gestational trophoblastic neoplasia?. Lancet. 364:705-707. DOI.
• Sebire NJ; Rees HC; Peston D; Seckl MJ; Newlands ES; Fisher RA. (Aug 2004). p57(KIP2) immunohistochemical staining of gestational trophoblastic tumours does not identify the type of the causative pregnancy. Histopathology. 45:135-141. DOI.
• Wenzel L; Berkowitz RS; Habbal R; Newlands E; Hancock B; Goldstein DP; Seckl M; Bernstein M; et al. (Aug 2004). Predictors of quality of life among long-term survivors of gestational trophoblastic disease. J Reprod Med. 49:589-594.
• Seckl MJ; Dhillon T; Dancey G; Foskett M; Paradinas FJ; Rees HC; Sebire N; Vigushin DM; et al. (Jul 2004). Increased gestational age at evacuation of a complete hydatidiform mole: does it correlate with increased risk of requiring chemotherapy?. J Reprod Med. 49:527-530.
• Madhusudan S; Tamir A; Bates N; Flanagan E; Gore ME; Barton DP; Harper P; Seckl M; et al. (1 May 2004). A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin Cancer Res. 10:2986-2996.
• Pandian Z; Seckl MJ; Smith R; Lees DA. (Apr 2004). Gestational choriocarcinoma: an unusual presentation with response to gemcitabine and surgery. BJOG. 111:382-384.
• McNeish IA; Kanfer EJ; Haynes R; Giles C; Harland SJ; Driver D; Rustin GJ; Newlands ES; et al. (22 Mar 2004). Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours. Br J Cancer. 90:1169-1175. DOI.
• Guppy AE; Nelstrop AE; Foster T; Agarwal R; Seckl MJ; Rustin GJ. (23 Feb 2004). A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer. Br J Cancer. 90:810-814. DOI.
• Wallace WHB; Collins MH; D'Angio GJ; Johnson EJ; Crofton PM; O'Neill JMD; Wilkinson AG; Mckenzie KJ; et al. (Dec 2003). Proceedings of the tumor board of the hospital for sick children, Edinburgh, UK - Infantile choriocarcinoma treated with chemotherapy alone. MED PEDIATR ONCOL. 41:550-557. DOI.
• Gaffan J; Holden L; Newlands ES; Short D; Fuller S; Begent RH; Rustin GJ; Seckl MJ. (17 Nov 2003). Infertility rates following POMB/ACE chemotherapy for male and female germ cell tumours - a retrospective long-term follow-up study. Br J Cancer. 89:1849-1854. DOI.
• Pardo OE; Lesay A; Arcaro A; Lopes R; Ng BL; Warne PH; McNeish IA; Tetley TD; et al. (Nov 2003). Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cells. Mol Cell Biol. 23:7600-7610.
• Hodges MD; Rees HC; Seckl MJ; Newlands ES; Fisher RA. (Aug 2003). Genetic refinement and physical mapping of a biparental complete hydatidiform mole locus on chromosome 19q13.4. J Med Genet. 40:e95.
• Sebire NJ; Fisher RA; Foskett M; Rees H; Seckl MJ; Newlands ES. (Jan 2003). Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy. BJOG. 110:22-26.
• Fisher RA; Hodges MD; Rees HC; Sebire NJ; Seckl MJ; Newlands ES; Genest DR; Castrillon DH. (15 Dec 2002). The maternally transcribed gene p57(KIP2) (CDNK1C) is abnormally expressed in both androgenetic and biparental complete hydatidiform moles. Hum Mol Genet. 11:3267-3272.
• Arcaro A; Khanzada UK; Vanhaesebroeck B; Tetley TD; Waterfield MD; Seckl MJ. (1 Oct 2002). Two distinct phosphoinositide 3-kinases mediate polypeptide growth factor-stimulated PKB activation. EMBO J. 21:5097-5108.
• Sebire NJ; Foskett M; Paradinas FJ; Fisher RA; Francis RJ; Short D; Newlands ES; Seckl MJ. (22 Jun 2002). Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin. Lancet. 359:2165-2166. DOI.
• Newlands ES; Holden L; Seckl MJ; McNeish I; Strickland S; Rustin GJ. (Jun 2002). Management of brain metastases in patients with high-risk gestational trophoblastic tumors. J Reprod Med. 47:465-471.
• Papadopoulos AJ; Foskett M; Seckl MJ; McNeish I; Paradinas FJ; Rees H; Newlands ES. (Jun 2002). Twenty-five years' clinical experience with placental site trophoblastic tumors. J Reprod Med. 47:460-464.
• Agarwal R; Strickland S; McNeish IA; Patel DC; Foskett M; Boultbee JE; Newlands ES; Seckl MJ. (May 2002). Doppler ultrasonography of the uterine artery and the response to chemotherapy in patients with gestational trophoblastic tumors. Clin Cancer Res. 8:1142-1147.
• Wenzel L; Berkowitz RS; Newlands E; Hancock B; Goldstein DP; Seckl MJ; Habbal R; Bernstein M; et al. (May 2002). Quality of life after gestational trophoblastic disease. J Reprod Med. 47:387-394.
• Seufferlein T; Seckl MJ; Schwarz E; Beil M; v Wichert G; Baust H; Lührs H; Schmid RM; et al. (8 Apr 2002). Mechanisms of nordihydroguaiaretic acid-induced growth inhibition and apoptosis in human cancer cells. Br J Cancer. 86:1188-1196. DOI.
• Pardo OE; Arcaro A; Salerno G; Raguz S; Downward J; Seckl MJ. (5 Apr 2002). Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis. J Biol Chem. 277:12040-12046. DOI.
• McNeish IA; Strickland S; Holden L; Rustin GJ; Foskett M; Seckl MJ; Newlands ES. (1 Apr 2002). Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol. 20:1838-1844.
• Lim AK; Agarwal R; Seckl MJ; Newlands ES; Barrett NK; Mitchell AW. (Mar 2002). Embolization of bleeding residual uterine vascular malformations in patients with treated gestational trophoblastic tumors. Radiology. 222:640-644.
• Blagden SP; Foskett MA; Fisher RA; Short D; Fuller S; Newlands ES; Seckl MJ. (7 Jan 2002). The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumours. Br J Cancer. 86:26-30. DOI.
• Sebire NJ; Foskett M; Fisher RA; Rees H; Seckl M; Newlands E. (Jan 2002). Risk of partial and complete hydatidiform molar pregnancy in relation to maternal age. BJOG. 109:99-102.
• McDonald RW; Bunjobpon W; Liu T; Fessler S; Pardo OE; Freer IK; Glaser M; Seckl MJ; et al. (Dec 2001). Synthesis and anticancer activity of nordihydroguaiaretic acid (NDGA) and analogues. Anticancer Drug Des. 16:261-270.
• Sebire NJ; Rees H; Paradinas F; Seckl M; Newlands E. (Dec 2001). The diagnostic implications of routine ultrasound examination in histologically confirmed early molar pregnancies. Ultrasound Obstet Gynecol. 18:662-665. DOI.
• Pardo OE; Arcaro A; Salerno G; Tetley TD; Valovka T; Gout I; Seckl MJ. (15 Nov 2001). Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells. Oncogene. 20:7658-7667. DOI.
• Paradinas FJ; Sebire NJ; Fisher RA; Rees HC; Foskett M; Seckl MJ; Newlands ES. (Nov 2001). Pseudo-partial moles: placental stem vessel hydrops and the association with Beckwith-Wiedemann syndrome and complete moles. Histopathology. 39:447-454.
• Sebire NJ; Rees H; Paradinas F; Fisher R; Foskett M; Seckl M; Newlands E. (Sep 2001). Extravillus endovascular implantation site trophoblast invasion is abnormal in complete versus partial molar pregnancies. Placenta. 22:725-728. DOI.
• Francis R; Bower M; Brunström G; Holden L; Newlands ES; Rustin GJ; Seckl MJ. (Oct 2000). Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options. Eur J Cancer. 36:1925-1932.
• Seckl MJ; Fisher RA; Salerno G; Rees H; Paradinas FJ; Foskett M; Newlands ES. (1 Jul 2000). Choriocarcinoma and partial hydatidiform moles. Lancet. 356:36-39. DOI.
• Newlands ES; Mulholland PJ; Holden L; Seckl MJ; Rustin GJ. (Feb 2000). Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol. 18:854-859.
• Hiorns LR; Seckl MJ; Paradinas F; Sharp SY; Skelton LA; Brunstrom G; Newlands ES; Kelland LR; et al. (Oct 1999). A molecular cytogenetic approach to studying platinum resistance. JOURNAL OF INORGANIC BIOCHEMISTRY. 77:95-104.
• Seckl MJ; Mulholland PJ; Bishop AE; Teale JD; Hales CN; Glaser M; Watkins S; Seckl JR. (2 Sep 1999). Hypoglycemia due to an insulin-secreting small-cell carcinoma of the cervix. N Engl J Med. 341:733-736.
• Lo SK; Montgomery JN; Blagden S; McNeish IA; Agarwal R; Suntharalingam J; Seckl MJ; Newlands ES. (12 Jun 1999). Reducing incidence of headache after lumbar puncture and intrathecal cytotoxics. LANCET. 353:2038-2039.
• Kanfer EJ; McGuigan D; Samson D; Abboudi Z; Abrahamson G; Apperley JF; Chilcott S; Craddock C; et al. (Oct 1998). High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels. Br J Cancer. 78:928-932.
• Woolas RP; Bower M; Newlands ES; Seckl M; Short D; Holden L. (Sep 1998). Influence of chemotherapy for gestational trophoblastic disease on subsequent pregnancy outcome. Br J Obstet Gynaecol. 105:1032-1035.
• Savage P; Roddie M; Seckl MJ. (4 Jul 1998). A 28-year-old woman with a pulmonary embolus. LANCET. 352:30-30.
• Christmas TJ; Doherty AP; Rustin GJ; Seckl MJ; Newlands ES. (Feb 1998). Excision of residual masses of metastatic germ cell tumours after chemotherapy: the role of extraperitoneal surgical approaches. Br J Urol. 81:301-308.
• Newlands ES; Bower M; Holden L; Short D; Seckl MJ; Rustin GJ; Begent RH; Bagshawe KD. (Feb 1998). Management of resistant gestational trophoblastic tumors. J Reprod Med. 43:111-118.
• Seckl MJ; Newlands ES. (Nov 1997). Treatment of gestational trophoblastic disease. Gen Diagn Pathol. 143:159-171.
• Christmas TJ; Doherty AP; Rustin GJ; Seckl MJ; Newlands ES. (Jul 1997). Primary retroperitoneal germ cell tumours: excision via a thoracoabdominal extraperitoneal approach. Br J Surg. 84:1022-1025.
• Seckl MJ; Higgins T; Widmer F; Rozengurt E. (1 Jan 1997). [D-Arg(1),D-Trp(5,7,9),Leu(11)]Substance P: A novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells. CANCER RES. 57:51-54.
• Seckl MJ; Higgins T; Rozengurt E. (15 Nov 1996). [D-Arg1,D-Trp5,7,9,Leu11]Substance P coordinately and reversibly inhibits bombesin- and vasopressin-induced signal transduction pathways in Swiss 3T3 cells. J Biol Chem. 271:29453-29460.
• Seckl MJ; Rozengurt E. (Feb 1996). Effect of tyrphostin combined with a substance P related antagonist on small cell lung cancer cell growth in vitro. Eur J Cancer. 32A:342-345.
• Seckl MJ; Newman RH; Freemont PS; Rozengurt E. (Apr 1995). Substance P-related antagonists inhibit vasopressin and bombesin but not 5'-3-O-(thio)triphosphate-stimulated inositol phosphate production in Swiss 3T3 cells. J Cell Physiol. 163:87-95. DOI.
• Seckl MJ; Morii N; Narumiya S; Rozengurt E. (24 Mar 1995). Guanosine 5'-3-O-(thio)triphosphate stimulates tyrosine phosphorylation of p125FAK and paxillin in permeabilized Swiss 3T3 cells. Role of p21rho. J Biol Chem. 270:6984-6990.
• Seckl MJ; Seufferlein T; Rozengurt E. (1 Dec 1994). Lysophosphatidic acid-depleted serum, hepatocyte growth factor and stem cell growth factor stimulate colony growth of small cell lung cancer cells through a calcium-independent pathway. Cancer Res. 54:6143-6147.
• Seckl M; Rozengurt E. (5 May 1993). Tyrphostin inhibits bombesin stimulation of tyrosine phosphorylation, c-fos expression, and DNA synthesis in Swiss 3T3 cells. J Biol Chem. 268:9548-9554.
• Seckl MJ; Rustin GJ; Coombes RC. (Nov 1992). CA-125 is not a useful marker in metastatic breast cancer. Br J Cancer. 66:875-876.
• Seckl MJ; Rustin GJ; Newlands ES; Gwyther SJ; Bomanji J. (23 Nov 1991). Pulmonary embolism, pulmonary hypertension, and choriocarcinoma. Lancet. 338:1313-1315.
• Seckl MJ; Rustin GJ; Bagshawe KD. (Jun 1990). Frequency of serum tumour marker monitoring in patients with non-seminomatous germ cell tumours. Br J Cancer. 61:916-918.
• SECKL MJ; RUSTIN GJS; BAGSHAWE KD. (May 1989). FREQUENCY OF SERUM TUMOR-MARKER MONITORING IN PATIENTS WITH NON-SEMINOMATOUS GERM-CELL TUMORS. BRIT J CANCER. 59:822-823.

Chapters in books

• McNeish I; Seckl MJ. Gene therapy approaches for cancer. In Gene therapy. 87-134. (2002).
• Newlands ES; Paradinas FJ; Seckl MJ. Ovarian germ-cell tumours and other rare ovarian tumours. In The Oxford textbook of oncology. 1809-1829. (2002).
• Seckl MJ; Paradinas FJ; Newlands ES. Gestational trophoblastic tumours. In The Oxford book of oncology 2nd edition. 1896-1897. (2002).

Conferences

• do Carmo CR; Seckl MJ; Costa-Pereira AP. A role for janus kinases in chemoresistance. Tri-Society Annual Conference of the International-Cytokine-Society/International-Society-of-Interferon-and-Cytokine-Research/Society-of-Leukocyte-Biology, 17 Oct 2009 - 21 Oct 2009. 48:126-126. ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD (Oct 2009). DOI.
• do Carmo CR; Seckl MJ; Costa-Pereira AP. A role for JAKs and STATs in chemoresistance?. 7th Joint Conference of the International-Cytokine-Society/International-Society-for-Interferon-and-Cytoklin-Research, 12 Oct 2008 - 16 Oct 2008. 43:238-238. ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD (Sep 2008). DOI.
• Savage P; Seckl M; Short D. Practical Issues in the Management of Low-Risk Gestational Trophoblast Tumors. 14th World Congress on Gestational Trophoblastic Diseases, 11 Nov 2007 - 14 Nov 2007. 53:774-780. SCI PRINTERS & PUBL INC (Oct 2008).
• Seckl MJ. HCG in diagnosis and management of gestational trophoblastic disease (GTD). 35th Meeting of the International-Society-for-Oncodevelopmental-Biology-and-Medicine, 15 Sep 2007 - 19 Sep 2007. 28:16-16. KARGER (Jan 2007).
• Nagai Y; Sebire NJ; Paradinas FJ; Fisher RA; Newlands ES; Savage PM; Seckl J. Placental site trophoblastic tumor (PSTT) treated at Charing Cross Hospital over 30 years. 12th Meeting of the International-Federation-of-Placenta-Association. 27:A56-A56. (Sep 2006).
• Seckl MJ; Rozengurt E. Substance P analogues act as broad-spectrum neuropeptide antagonists. 2nd Symposium on Design, Synthesis and Structure of Peptidomimetics. 5:199-204. (May 1998).
• Seckl MJ; Rozengurt E. Neuropeptides, signal transduction and small cell lung cancer. Workshop on Prevention and Early Detection of Lung Cancer. 129-142. (1998).
• Newlands ES; Foskett MA; Seckl MJ; Paradinas FJ; Francis R; Short D; Fuller S; Hall JF. The management and outcome in patients presenting with twin/multiple pregnancies complicated by a complete hydatidiform mole (CHM) and patients presenting with partial hydatidiform mole (PHM). 7th Biennial Meeting of the International Gynecologic Cancer Society. 43-47. (1999).
• Sebire NJ; Fisher RA; Rees H; Seckl M. Histomorphological examination and flow cytometric ploidy analysis in the diagnosis of early hydatidiform mole. 2nd Joint Meeting of the British Division of the International-Academy-of-Pathology/185th Meeting of the Pathological-Society-of-Great-Britian-and-Ireland. 201:52A-52A. (Sep 2003).
• Dhillon T; Palmieri C; Newlands E; Franks J; Seckl M. Whole body positron emission tomography (PET) for the detection of residual disease in gestational trophoblastic tumors (GTTs). 41st Annual Meeting of the American-Society-of-Clinical-Oncology. 23:481S-481S. (1 Jun 2005).
• Lindsay I; Fowler DJ; Fisher R; Seckl M; Sebire NJ. Role of central review for the histopathological diagnosis of complete and partial hydatidiform moles in southern England. 3rd Joint Meeting of the British Division of the International-Academy-of-Pahtology/Meeting of the Pathological-Society-of-Great-Britian-and-Ireland. 207:18-18. (Oct 2005).
• Sebire NJ; Lindsay I; Seckl M. Difficulties in the histopathological diagnosis of tubal complete and partial hydatidiform moles. 3rd Joint Meeting of the British Division of the International-Academy-of-Pahtology/Meeting of the Pathological-Society-of-Great-Britian-and-Ireland. 207:18-18. (Oct 2005).
• Powles T; Young A; Short D; Savage P; Pappin C; Schmid P; Seckl M. The outcome of patients with relapsed gestational trophoblastic neoplasm (GTN) after the completion of chemotherapy. 42nd Annual Meeting of the American-Society-of-Clinical-Oncology. 24:263S-263S. (20 Jun 2006).
• Goldstraw MA; Christmas T; Seckl MJ. The fibroblast growth factor receptor inhibitor PD0173074 as a potential novel anti-prostate cancer therapy. Annual Meeting of the British-Association-of-Urological-Surgeons. 99:29-29. (Jun 2007).
• Gabriel I; Chaidos A; Giles C; Apperley J; Seckl M; Bower M; Kanfer E. The role of high dose chemotherapy and peripheral blood stem cell support in refractory trophoblastic disease and non-gestational choriocarcinoma: A review of eight patients. 12th Congress of the European-Hematology-Association. 92:185-185. (Jun 2007).
• Fowler DJ; Lindsay I; Seckl M; Sebire NJ. Diagnosis of intraplacental choriocarcinoma and relationship with infantile choriocarcinoma: Four additional cases. 3rd Joint Meeting of the British Division of the International-Academy-of-Pahtology/Meeting of the Pathological-Society-of-Great-Britian-and-Ireland, 5 Jul 2005 - 8 Jul 2005. 207:18-18. JOHN WILEY & SONS LTD (Oct 2005).
• Fowler DJ; Lindsay I; Seckl M; Sebire NJ. Pathological-ultrasound correlation of routine sonographic examination in the diagnosis of hydatidiform mole: experience of > 1,000 cases from a regional centre. 3rd Joint Meeting of the British Division of the International-Academy-of-Pahtology/Meeting of the Pathological-Society-of-Great-Britian-and-Ireland, 5 Jul 2005 - 8 Jul 2005. 207:18-18. JOHN WILEY & SONS LTD (Oct 2005).
• Seckl M; Dhillon T; Young AM; Mitchell H; Newlands ES; Hancock B; Palmieri C. Management and outcome of healthy women with a persistently elevated serum beta-hCG. 41st Annual Meeting of the American-Society-of-Clinical-Oncology, 13 May 2005 - 17 May 2005. 23:475S-475S. AMER SOC CLINICAL ONCOLOGY (1 Jun 2005).